The estimated Net Worth of Saira Ramasastry is at least $992 mil dollars as of 11 June 2024. Ms. Ramasastry owns over 4,000 units of Vir Biotechnology Inc stock worth over $114,467 and over the last 12 years she sold VIR stock worth over $323,829. In addition, she makes $553,663 as Independent Director at Vir Biotechnology Inc.
Saira has made over 13 trades of the Vir Biotechnology Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she sold 4,000 units of VIR stock worth $43,800 on 11 June 2024.
The largest trade she's ever made was exercising 10,000 units of Vir Biotechnology Inc stock on 19 May 2021 worth over $127,600. On average, Saira trades about 1,784 units every 75 days since 2012. As of 11 June 2024 she still owns at least 14,619 units of Vir Biotechnology Inc stock.
You can see the complete history of Ms. Ramasastry stock trades at the bottom of the page.
Saira Ramasastry serves as Independent Director of the Company. Ms. Ramasastry has served as Managing Partner of Life Sciences Advisory, LLC since April 2009, a company that she founded to provide strategic advice, business development solutions and innovative financing strategies for the life sciences industry. Ms. Ramasastry also serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research, and as business and sustainability lead for the European Prevention of Alzheimer’s Dementia consortium. From August 1999 to March 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Co., Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry currently serves on the board of directors of the following public companies: Sangamo Therapeutics Inc., Cassava Sciences, Inc., Innovate Biopharmaceuticals, Inc., and Glenmark Pharmaceuticals, Ltd. Ms. Ramasastry will step down from the board of directors of Innovate Biopharmaceuticals, Inc. in connection with its proposed merger with RDD Pharma Ltd., which is expected to close early in the second quarter of 2020.
As the Independent Director of Vir Biotechnology Inc, the total compensation of Saira Ramasastry at Vir Biotechnology Inc is $553,663. There are 12 executives at Vir Biotechnology Inc getting paid more, with George Scangos having the highest compensation of $3,944,610.
Saira Ramasastry is 44, she's been the Independent Director of Vir Biotechnology Inc since 2019. There are 22 older and 1 younger executives at Vir Biotechnology Inc. The oldest executive at Vir Biotechnology Inc is Phillip Sharp, 75, who is the Independent Director.
Saira's mailing address filed with the SEC is C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158.
Over the last 5 years, insiders at Vir Biotechnology Inc have traded over $197,171,926 worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth $139,246,875 . The most active insiders traders include Norbert W Bischofberger, Endurance (Cayman) Ltd Sb I..., eKristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of $478,115. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth $95,082.
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
Vir Biotechnology Inc executives and other stock owners filed with the SEC include: